India’s Growing CRAMS Sector Faces New Challenges
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - With an estimated annual growth of 25 percent, the Indian contract research and manufacturing services sector is attracting global attention as untapped potential for global pharmaceutical firms, but industry experts say working with India CRAMS brings several challenges
You may also be interested in...
CROs in Asian Giants India and China Create Alliance To Conduct Clinical Trials To Keep Pace With Exploding Demand
BEIJING - In response to rapidly accelerating demand for clinical drug research across Asia, India's GVK Biosciences and China's Excel PharmaStudies are crafting an alliance to jointly conduct trials in both countries
CROs in Asian Giants India and China Create Alliance To Conduct Clinical Trials To Keep Pace With Exploding Demand
BEIJING - In response to rapidly accelerating demand for clinical drug research across Asia, India's GVK Biosciences and China's Excel PharmaStudies are crafting an alliance to jointly conduct trials in both countries
India’s CRAMS Market Set To Leap To $2.46 Billion By 2010
MUMBAI - Low-cost and high-end formulation manufacturing capacity is propelling the growth of Indian contract manufacturers and the sector is poised to reach an estimated $2.46 billion by 2010. From the current level of $869 million, the contract research and manufacturing services sector will show an annual growth of 41.7 percent, according to a joint study by the Confederation of Indian Industries and the global consulting firm KPMG